{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:06:34Z","timestamp":1740135994539,"version":"3.37.3"},"reference-count":29,"publisher":"Japanese Society for Hygiene","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Environ Health Prev Med","Environ. Health Prev. Med."],"published-print":{"date-parts":[[2023]]},"DOI":"10.1265\/ehpm.22-00222","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T22:40:45Z","timestamp":1692398445000},"page":"46-46","source":"Crossref","is-referenced-by-count":3,"title":["Loss of social independence in patients with neurofibromatosis type 2: a follow-up study using a national registry in Japan"],"prefix":"10.1265","volume":"28","author":[{"given":"Hiroto","family":"Okoshi","sequence":"first","affiliation":[{"name":"Department of Public Health and Environmental Medicine, The Jikei University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Public Health and Environmental Medicine, The Jikei University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8392-1870","authenticated-orcid":false,"given":"Machi","family":"Suka","sequence":"additional","affiliation":[{"name":"Department of Public Health and Environmental Medicine, The Jikei University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"The Jikei University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masazumi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fukushima Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Nishigori","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Kobe University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"335","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, et al. Neurofibromatosis type 2. Lancet. 2009;373(9679):1974\u201386.","DOI":"10.1016\/S0140-6736(09)60259-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005;26(1):93\u20137.","DOI":"10.1097\/00129492-200501000-00016"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4;16.","DOI":"10.1186\/1750-1172-4-16"},{"key":"4","unstructured":"4. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84(304):603\u201318."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Odat HA, Piccirillo E, Sequino G, Taibah A, Sanna M. Management strategy of vestibular schwannoma in neurofibromatosis type 2. Otol Neurotol. 2011;32(7):1163\u201370.","DOI":"10.1097\/MAO.0b013e3182267f17"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Patel CM, Ferner R, Grunfeld EA. A qualitative study of the impact of living with neurofibromatosis type 2. Psychol Health Med. 2011;16(1):19\u201328.","DOI":"10.1080\/13548506.2010.516363"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Okoshi H, Yamauchi T, Suka M, Saito K, Nishigori C, Yanagisawa H. Social Independence of Patients with Neurofibromatosis Type 2 in Japan: Analysis of a National Registry of Patients Receiving Medical Expense Subsidies, 2004\u20132013. Neurol Med Chir (Tokyo). 2020;60(9):450\u20137.","DOI":"10.2176\/nmc.oa.2020-0106"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, et al; English Specialist NF2 Research Group, Friedman JM, Evans DG. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet. 2015;52(10):699\u2013705.","DOI":"10.1136\/jmedgenet-2015-103290"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71(4):715\u201323.","DOI":"10.1086\/342716"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Seidlin M, Holzman R, Knight P, Korf B, Rangel Miller V, Viskochil D, et al; Children\u2019s Tumor Foundation. Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: An observational study. PLoS One. 2017;12(6):e0178639.","DOI":"10.1371\/journal.pone.0178639"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Matsuo M, Ohno K, Ohtsuka F. Characterization of early onset neurofibromatosis type 2. Brain Dev. 2014;36(2):148\u201352.","DOI":"10.1016\/j.braindev.2013.01.007"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Iwatate K, Yokoo T, Iwatate E, Ichikawa M, Sato T, Fujii M, et al. Population Characteristics and Progressive Disability in Neurofibromatosis Type 2. World Neurosurg. 2017;106:653\u201360.","DOI":"10.1016\/j.wneu.2017.07.036"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Otsuka G, Saito K, Nagatani T, Yoshida J. Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2. J Neurosurg. 2003;99(3):480\u20133.","DOI":"10.3171\/jns.2003.99.3.0480"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yamauchi T, Suka M, Nishigori C, Yanagisawa H. Evaluation of neurofibromatosis type 1 progression using a nationwide registry of patients who submitted claims for medical expense subsidies in Japan between 2008 and 2012. Orphanet J Rare Dis. 2019;14(1):166.","DOI":"10.1186\/s13023-019-1148-8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11\u201313, 1991. The Consensus Development Panel. Arch Neurol. 1994;51(2):201\u20137.","DOI":"10.1001\/archneur.1994.00540140115021"},{"key":"16","unstructured":"16. Japan Intractable Diseases Information Center. Neurofibromatosis. http:\/\/www.nanbyou.or.jp\/. Accessed March 17, 2021."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Aboukais R, Baroncini M, Zairi F, Bonne NX, Schapira S, Vincent C, et al. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. Acta Neurochir (Wien). 2013;155(5):771\u20137.","DOI":"10.1007\/s00701-012-1590-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Evans DG, Trueman L, Wallace A, Collins S, Strachan T. Genotype\/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998;35(6):450\u20135.","DOI":"10.1136\/jmg.35.6.450"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ruggieri M. The different forms of neurofibromatosis. Childs Nerv Syst. 1999 Jul;15(6\u20137):295\u2013308.","DOI":"10.1007\/s003810050398"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ruggieri M, Pratic\u00f2 AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, et al. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngol Ital. 2016;36(5):345\u201367.","DOI":"10.14639\/0392-100X-1093"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lin HW, Mahboubi H, Bhattacharyya N. Self-reported Hearing Difficulty and Risk of Accidental Injury in US Adults, 2007 to 2015. JAMA Otolaryngol Head Neck Surg. 2018;144(5):413\u20137.","DOI":"10.1001\/jamaoto.2018.0039"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Liu CM, Lee CT. Association of Hearing Loss With Dementia. JAMA Netw Open. 2019;2(7):e198112.","DOI":"10.1001\/jamanetworkopen.2019.8112"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kim BS, Seol HJ, Lee JI, Shin HJ, Park K, Kong DS, et al. Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges. Neurosurg Rev. 2016;39(4):643\u201353.","DOI":"10.1007\/s10143-016-0728-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tan H, Jia H, Li Y, Zhang Z, Zhu W, Cai Y, et al. Impact of cochlear implantation on the management strategy of patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol. 2018;275(11):2667\u201374.","DOI":"10.1007\/s00405-018-5127-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sanna M, Di Lella F, Guida M, Merkus P. Auditory brainstem implants in NF2 patients: results and review of the literature. Otol Neurotol. 2012;33(2):154\u201364.","DOI":"10.1097\/MAO.0b013e318241bc71"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046\u201352.","DOI":"10.1097\/MAO.0b013e31825e73f5"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Fujii M, Kobayakawa M, Saito K, Inano A, Morita A, Hasegawa M, et al, On Behalf Of The BeatNF Trial Investigators. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma. Curr Oncol. 2021;28(1):726\u201339.","DOI":"10.3390\/curroncol28010071"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, et al. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 2012;14(12):977\u201382.","DOI":"10.1038\/gim.2012.85"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Fukuda Y, Hiyoshi A. Influences of income and employment on psychological distress and depression treatment in Japanese adults. Environ Health Prev Med. 2012;17(1):10\u20137.","DOI":"10.1007\/s12199-011-0212-3"}],"container-title":["Environmental Health and Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ehpm\/28\/0\/28_22-00222\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T05:00:23Z","timestamp":1692421223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ehpm\/28\/0\/28_22-00222\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":29,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1265\/ehpm.22-00222","relation":{},"ISSN":["1342-078X","1347-4715"],"issn-type":[{"type":"print","value":"1342-078X"},{"type":"electronic","value":"1347-4715"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"22-00222"}}